biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

[prophetoffactz]

"And the market is saying the deal and all the little deals within it are collectively worth less than 4¢."

That's what you think it's worth. BTI and Midatech shareholders actually got a ~15% fully diluted share position in Biodexa. If the deal and financing closes the deal and financial status of Biodexa will be de-risked. The financing could result in a US$20 million cash injection to advance the business with warrant exercise. If additonal cash is raised near-term as appears likely and Biodexa can get to hard data clinical milestones with its lead asset the company will be further de-risked. The lead assets target markets worth $12 billion. What's a 10%-15%-20% chance at $12 billion worth. Biodexa's cancer assets could bring in cashflow in the relatively near termto support an expansive xB3, Q-Sphera pipeline in future years limiting dilution. If J&J signes multi-product licensing deals on xB3 and Q-Sphera the platforms will be additionally de-risked. If Chiesi and a cancer deal are signed there is addiitonal value and with the scale of Biodexa and its infrastructure deals can be more meaningful. Biodexa could be a development partner.

What could Biodexa's share price be worth in 2 years under a reasonable best case scenerio given the various assets? The dilution came with massive potential upside but if the only thing you want to calculate is the dilution there is a problem. This is a big, bold, and aggressive attempt to address the challenges in the biotech market at this time.